Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Reinisch, Walter"" wg kryterium: Autor


Tytuł :
Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II.
Autorzy :
Reinisch W; Medical University of Vienna, Vienna, Austria.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Danese S; Humanitas University, Milan, Italy.
Hébuterne X; University of Nice Sophia Antipolis, CHU of Nice, Nice, France.
Kłopocka M; Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
Tarabar D; Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia.
Vaňásek T; Charles University Hospital, Hradec Králové, Czech Republic.
Greguš M; Gastroenterology Centre, Nitra, Slovakia.
Hellstern PA; Nature Coast Clinical Research, Inverness, FL, USA.
Kim JS; Seoul National University College of Medicine, Seoul, South Korea.
Sparrow MP; Alfred Hospital, Melbourne, VIC, Australia.
Gorelick KJ; Zymo Consulting Group, Newtown Square, PA, USA.
Hoy M; Shire, a Takeda company, Lexington, MA, USA.
Goetsch M; Shire, a Takeda company, Zug, Switzerland.
Bliss C; Shire, a Takeda company, Lexington, MA, USA.
Gupta C; Cytel Inc, Cambridge, MA, USA.
Cataldi F; Shire, a Takeda company, Lexington, MA, USA.
Vermeire S; University Hospitals Leuven, Leuven, Belgium.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2021 Feb 18. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Autorzy :
Winthrop KL; Oregon Health & Science University, Portland , OR,  USA.
Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester , MN,  USA.
Baumgart DC; Division of Gastroenterology, University of Alberta, Edmonton , AB,  Canada.
Reinisch W; Medical University of Vienna , Vienna,  Austria.
Nduaka CI; Pfizer Inc, Collegeville , PA,  USA.
Lawendy N; Pfizer Inc, Collegeville , PA,  USA.
Chan G; Pfizer Inc, Collegeville , PA,  USA.
Mundayat R; Pfizer Inc, New York , NY,  USA.
Friedman GS; Pfizer Inc, Collegeville , PA,  USA.
Salese L; Pfizer Inc, Collegeville , PA,  USA.
Thorpe AJ; Pfizer Inc, Collegeville , PA,  USA.
Su C; Pfizer Inc, Collegeville , PA,  USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 27. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
End of Induction Patient Reported Outcomes Predict Clinical Remission but not Endoscopic Remission in Crohn's Disease.
Autorzy :
Wong ECL; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Buffone E; McGill University, Montreal, QC, Canada.
Lee SJ; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel, Vienna, Austria.
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Nov 27. Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.
Autorzy :
Reinisch W; Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Danese S; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Peyrin-Biroulet L; Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.
Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Oct 21; Vol. 14 (Supplement_3), pp. S815-S819.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Betacoronavirus*
Anti-Inflammatory Agents/*therapeutic use
Clinical Trials as Topic/*standards
Coronavirus Infections/*prevention & control
Gastrointestinal Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Research Design/*standards
COVID-19 ; Clinical Trials as Topic/methods ; Coronavirus Infections/complications ; Global Health ; Humans ; Infection Control/methods ; Infection Control/standards ; Inflammatory Bowel Diseases/complications ; Pneumonia, Viral/complications ; Risk Management/methods ; Risk Management/standards ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.
Autorzy :
Reinisch W; Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Danese S; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Peyrin-Biroulet L; Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.
Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Oct 21; Vol. 14 (Supplement_3), pp. S820.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Week 6 Calprotectin Best Predicts Likelihood of Long-Term Endoscopic Healing in Crohn's Disease: A Post-Hoc Analysis of the UNITI/IM-UNITI Trials.
Autorzy :
Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Wong ECL; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, WähringerGürtel, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Sep 15. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Autorzy :
Panés J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindsay JO; Department of Gastrointestinal and Liver Services, Royal London Hospital, Barts Health NHS Trust, London, UK.
Teich N; Innere Medizin/Gastroenterologie, Internistische Gemeinschaftspraxis, Leipzig, Germany.
Lindgren S; Department of Gastroenterology, Lund University, Malmo, Sweden.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Flynn HA; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Huyck S; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Stryszak P; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Yao R; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Philip G; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Universitätsklinik für Innere Medizin III, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1148-1157.
Typ publikacji :
Comparative Study; Journal Article; Observational Study
MeSH Terms :
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adrenal Cortex Hormones/therapeutic use ; Adult ; Europe ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Immunosuppressive Agents/therapeutic use ; Infections/chemically induced ; Infliximab/adverse effects ; Male ; Product Surveillance, Postmarketing ; Prospective Studies ; Registries
Czasopismo naukowe
Tytuł :
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.
Autorzy :
Hanauer S; Northwestern University, Digestive Health Centre, Chicago, IL, USA.
Sandborn WJ; University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA.
Colombel JF; Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, NY, USA.
Vermeire S; University Hospital Leuven, Gastroenterology, Leuven, Belgium.
Petersson J; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Kligys K; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Zhou Q; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Lazar A; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Reinisch W; Medical University of Vienna, Department for Gastroenterology and Hepatology, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1227-1233.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Colitis, Ulcerative/*drug therapy
Adult ; Aged ; Biomarkers/blood ; Blood Proteins/analysis ; C-Reactive Protein/analysis ; Colitis, Ulcerative/pathology ; Erythrocyte Count ; Female ; Hematocrit ; Hemoglobins/analysis ; Humans ; Intestinal Mucosa/pathology ; Male ; Middle Aged ; Platelet Count ; Quality of Life ; Serum Albumin/analysis ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
Autorzy :
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Gibson PR; Monash University and Alfred Hospital, Melbourne, VIC, Australia.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Strauss R; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Johanns J; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Padgett L; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Adedokun OJ; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Collins J; Oregon Health & Science University and Portland VA Medical Center, Portland, OR, USA.
Rutgeerts P; Division of Gastroenterology and Hepatology, University of Leuven, Gasthuisberg, Leuven, Belgium.
Tarabar D; Department of Gastroenterology, Military Medical Academy, Belgrade, Serbia.
Marano C; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2018 Aug 29; Vol. 12 (9), pp. 1053-1066.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Colitis, Ulcerative/*drug therapy
Adolescent ; Adult ; Aged ; Cohort Studies ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Remission Induction ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
Autorzy :
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Hung K; Pfizer Inc, Precision Medicine, Cambridge, MA, USA.
Hassan-Zahraee M; Early Clinical R&D | Precision Medicine, Pfizer Inc, Cambridge, MA, USA.
Cataldi F; Cataldi Research Solutions, Beverly, MA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2018 Aug 22; Vol. 12 (suppl_2), pp. S669-S677.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Gastrointestinal Agents/*therapeutic use
Immunoglobulins/*metabolism
Inflammatory Bowel Diseases/*drug therapy
Intercellular Adhesion Molecule-1/*metabolism
Mucoproteins/*metabolism
Phosphorothioate Oligonucleotides/*therapeutic use
Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cell Adhesion Molecules ; Cell Movement ; Humans ; Immunoglobulins/immunology ; Intercellular Adhesion Molecule-1/immunology ; Leukocytes/immunology ; Molecular Targeted Therapy ; Mucoproteins/antagonists & inhibitors ; Mucoproteins/immunology ; Pouchitis/drug therapy
Czasopismo naukowe
Tytuł :
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy :
Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2018 Mar 28; Vol. 12 (4), pp. 510.
Typ publikacji :
Journal Article; Published Erratum
Czasopismo naukowe
Tytuł :
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
Autorzy :
D'Haens G; Academic Medical Center, Amsterdam, The Netherlands.
Vermeire S; Leuven University Hospital, Leuven, Belgium.
Vogelsang H; Medical University of Vienna, Vienna, Austria.
Allez M; Hôpital Saint-Louis, Université Paris Diderot, Paris, France.
Desreumaux P; University of Lille, Lille, France.
Van Gossum A; Erasme Hospital, Free University of Brussels, Brussels, Belgium.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Baumgart DC; Charité Medical School, Humboldt-University of Berlin, Berlin, Germany.
Ransohoff RM; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Comer GM; Kimberton Drug Development Consulting, Phoenixville, PA, USA.
Ahmad A; Pfizer, Cambridge, MA, USA.
Cataldi F; Pfizer, Cambridge, MA, USA.
Cheng J; Pfizer, Cambridge, MA, USA.
Clare R; Pfizer, Cambridge, MA, USA.
Gorelick KJ; Pfizer, Cambridge, MA, USA.
Kaminski A; Pfizer, Cambridge, MA, USA.
Pradhan V; Pfizer, Cambridge, MA, USA.
Rivers S; Pfizer, Cambridge, MA, USA.
Sikpi MO; Pfizer, Cambridge, MA, USA.
Zhang Y; Pfizer, Cambridge, MA, USA.
Hassan-Zahraee M; Pfizer, Cambridge, MA, USA.
Reinisch W; Medical University of Vienna, Vienna, Austria.; McMaster University, Hamilton, ON, Canada.
Stuve O; Neurology Section, VA North Texas Health Care System, Dallas, TX, USA.; Southwestern Medical Center, University of Texas, Dallas, TX, USA.; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2018 Jan 24; Vol. 12 (2), pp. 188-196.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Central Nervous System/*immunology
Crohn Disease/*immunology
Integrin beta Chains/*metabolism
T-Lymphocytes/*metabolism
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/pharmacology ; Crohn Disease/blood ; Crohn Disease/cerebrospinal fluid ; Female ; Humans ; Immunologic Surveillance/drug effects ; Immunosuppressive Agents/therapeutic use ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Lymphocyte Count ; Male ; Middle Aged ; T-Lymphocyte Subsets ; Young Adult
Czasopismo naukowe
Tytuł :
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy :
Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Aug 01; Vol. 11 (8), pp. 921-929.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/blood ; Dose-Response Relationship, Drug ; Double-Blind Method ; Feces/chemistry ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Male ; Middle Aged ; Remission Induction/methods ; Serum Albumin/analysis ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Autorzy :
D'Haens G; Department of Gastroenterology, Academic MedicalCenter, Amsterdam, The Netherlands.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Medical University, Vienna, Austria and McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Ghosh S; Department of Gastroenterology, University of Calgary, Calgary, AB, Canada.
Prantera C; Department of Gastroenterology, A.O. San Camillo Forlanini, Rome, Italy.
Lindgren S; Department of Gastroenterology, Lund University, University Hospital Skane, Malmö, Sweden.
Hommes DW; Centre for Inflammatory Bowel Diseases, Univerisity of California Los Angeles, Los Angeles, CA, USA.
Huang Z; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Boice J; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Huyck S; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International GmbH, Lucerne, Switzerland.
Pokaż więcej
Corporate Authors :
ENCORE investigators
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jun 01; Vol. 11 (6), pp. 680-689.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Crohn Disease/*drug therapy
Gastrointestinal Agents/*adverse effects
Hematologic Diseases/*chemically induced
Infections/*chemically induced
Infliximab/*adverse effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents/adverse effects ; Azathioprine/adverse effects ; Demyelinating Diseases/chemically induced ; Drug Substitution ; Drug Therapy, Combination/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infusions, Intravenous/adverse effects ; Lymphoproliferative Disorders/chemically induced ; Male ; Mercaptopurine/adverse effects ; Mesalamine/adverse effects ; Methotrexate/adverse effects ; Middle Aged ; Mortality ; Narcotics/adverse effects ; Prednisone/adverse effects ; Prospective Studies ; Registries ; Risk Factors ; Sulfasalazine/adverse effects ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Autorzy :
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada; and Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Colombel JF; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
D'Haens G; Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands; and Imelda GI Clinical Research Center, Bonheiden, Belgium.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Rutgeerts P; Division of Gastroenterology, Department of Internal Medicine, University of Leuven, Leuven, Belgium.
Geboes K; Department of Pathology, University of Leuven, Leuven, Belgium.
Petersson J; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Eichner S; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Zhou Q; Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA.
Robinson AM; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Read HA; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Thakkar R; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Apr 01; Vol. 11 (4), pp. 425-434.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Adalimumab/*therapeutic use
Crohn Disease/*drug therapy
Adult ; Colonoscopy ; Crohn Disease/pathology ; Double-Blind Method ; Female ; Humans ; Intestinal Mucosa/pathology ; Male ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Autorzy :
Adedokun OJ; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA .
Xu Z; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
Marano CW; Department of Clinical Development Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Strauss R; Department of Translational Medicine Sciences, Janssen Research & Development, LLC, Spring House, PA, USA.
Zhang H; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
Johanns J; Department of Clinical Biostatistics, Janssen Research & Development, LLC, Spring House, PA, USA.
Zhou H; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
Davis HM; Department of Biologics Development Sciences, Janssen Research & Development, LLC, Spring House, PA, USA.
Reinisch W; Department of Gastroenterology, Universitätsklinik für Innere Medizin III, Vienna, Austria & McMaster University, Hamilton, ON, Canada.
Feagan BG; Department of Gastroenterology, Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Rutgeerts P; Department of Gastroenterology, Hospital Gasthuisberg, Leuven, Belgium.
Sandborn WJ; Department of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jan; Vol. 11 (1), pp. 35-46. Date of Electronic Publication: 2016 Jul 20.
Typ publikacji :
Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Colitis, Ulcerative/*drug therapy
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/pharmacokinetics ; Colitis, Ulcerative/pathology ; Female ; Humans ; Male ; Middle Aged ; Remission Induction ; Severity of Illness Index ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs.
Autorzy :
Gecse KB; First Department of Medicine, Semmelweis University, Budapest, Hungary .
Sebastian S; Inflammatory Bowel Disease Unit, Hull & East Yorkshire NHS Trust, Hull, UK.
Hertogh Gd; Department of Pathology, University of Leuven, Leuven, Belgium.
Yassin NA; Department of Colorectal Surgery, St Mark's Hospital and Academic Institute, London, UK.
Kotze PG; Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, PR, Brazil.
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Spinelli A; Colorectal Surgery Unit, Humanitas Research Hospital, Humanitas University, Milan, Italy.
Koutroubakis IE; Department of Gastroenterology, University Hospital Heraklion, Iraklio, Greece.
Katsanos KH; Division of Gastroenterology, Department of Medicine, School of Health Sciences, Ioannina, Greece.
Hart A; Inflammatory Bowel Disease Unit, St Mark's Hospital, London, UK.
van den Brink GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Rogler G; Division of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Bemelman WA; Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2016 Jul; Vol. 10 (7), pp. 758-65. Date of Electronic Publication: 2016 Jan 28.
Typ publikacji :
Consensus Development Conference; Journal Article; Systematic Review
MeSH Terms :
Crohn Disease/*physiopathology
Rectal Fistula/*etiology
Crohn Disease/therapy ; Humans ; Magnetic Resonance Imaging ; Outcome Assessment, Health Care/methods ; Rectal Fistula/diagnosis ; Rectal Fistula/pathology ; Rectal Fistula/therapy ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
Autorzy :
Sandborn WJ; Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA .
Colombel JF; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghosh S; Department of Medicine, University of Calgary, Calgary, AB, Canada.
Sands BE; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dryden G; Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.
Hébuterne X; Faculté de Médecine, Université de Nice-Sophia Antipolis, Hôpital de l'Archet, Nice, France.
Leong RW; Concord Hospital, Gastroenterology and Liver Services, University of New South Wales, Sydney, Australia.
Bressler B; Division of Gastroenterology, St Paul's Hospital, Vancouver, BC, Canada.
Ullman T; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and McMaster University, Department of Internal Medicine, Hamilton, ON, Canada.
Xu LA; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Luo A; Formerly of Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2016 Apr; Vol. 10 (4), pp. 418-28. Date of Electronic Publication: 2015 Dec 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Chemokine CXCL10/*antagonists & inhibitors
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Remission Induction ; Young Adult
Czasopismo naukowe
Tytuł :
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
Autorzy :
Travis SP; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK .
Schnell D; Middletown, OH, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Abreu MT; Division of Gastroenterology, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA.
Altman DG; Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
Hanauer SB; Digestive Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Krzeski P; Medpace, Warsaw, Poland.
Lichtenstein GR; Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Marteau PR; AP-HP, Hôpital Lariboisière Medicosurgical Department of Digestive Diseases and University Denis Diderot, Paris, France.
Mary JY; INSERM U717 Biostatistics and Clinical Epidemiology, Université Paris Diderot, Paris, France.
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Schnell P; University of Minnesota, Minneapolis, MN, USA.
Yacyshyn BR; Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH, USA.
Colombel JF; Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France.
Bernhardt CA; Bernhardt Regulatory Consulting, Cincinnati, OH, USA.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2015 Aug; Vol. 9 (8), pp. 607-16. Date of Electronic Publication: 2015 May 08.
Typ publikacji :
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Sigmoidoscopy*
Colitis, Ulcerative/*diagnosis
Humans ; Observer Variation ; Single-Blind Method ; Video Recording
Czasopismo naukowe
Tytuł :
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative.
Autorzy :
Danese S; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy .
Fiorino G; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
Mary JY; Inserm U1153 - SBIM Hôpital Saint-Louis, Paris, France.
Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
D'Haens G; IBD Unit, Gastroenterology, Amsterdam Medical Center, Amsterdam, The Netherlands.
Moja L; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Unit of Clinical Epidemiology, IRCCS Galeazzi Orthopedic Institute, Milan, Italy.
D'Hoore A; Abdominal Surgery, UZ Leuven, Leuven, Belgium.
Panes J; Gastroenterology Department, Hospital Clinic of Barcelona, IDIPABS, CIBERehd, Barcelona, Spain.
Reinisch W; Medizinische Universität Wien, Klinische Abt. Gastroenterologie & Hepatologie, AKH Wien, Austria.
Sandborn WJ; Division of Gastroenterology, UC San Diego Health System, La Jolla, CA, USA.
Travis SP; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
Vermeire S; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Peyrin-Biroulet L; Department of Hepato-Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France.
Colombel JF; Department of Gastroenterology, Icahn Medical School at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2015 Aug; Vol. 9 (8), pp. 601-6. Date of Electronic Publication: 2015 Apr 23.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Decision Support Techniques*
Health Status Indicators*
Referral and Consultation*
Crohn Disease/*diagnosis
Adult ; Cross-Sectional Studies ; Delayed Diagnosis/prevention & control ; Early Diagnosis ; Humans ; Risk Assessment ; Sensitivity and Specificity ; Surveys and Questionnaires
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies